Heart Attack Heart Disease Innovation 
DAIC
MARCH 6, 2024
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.
DAIC
JANUARY 28, 2025
An improved understanding of heart development could help inform new clinical strategies in managing congenital heart diseases, which are the most common type of birth defects, said research team leader Shang Wang from Stevens Institute of Technology.
DAIC
FEBRUARY 9, 2024
Photo by Cedars-Sinai Raj Makkar, MD , associate director of the Smidt Heart Institute and vice president of Cardiovascular Innovation and Intervention for Cedars-Sinai, was the principal investigator for the TRISCEND II trial at Cedars-Sinai. Moderate and severe tricuspid disease is common in the U.S. Raj Makkar, MD.
GEMMS
AUGUST 29, 2024
By excelling in processing and analyzing vast datasets, AI algorithms can detect early signs of heart disease that may be challenging for even the most experienced cardiologists to identify. Reach out today to learn more about our innovative solutions and how they can transform your practice.
DAIC
DECEMBER 14, 2023
The typical survival rate of this deadly complication during a heart attack has historically hovered around 50%. The National Cardiogenic Shock Initiative is the largest prospective study of therapy for severe heart attack cardiogenic shock done in the United States in the past two decades,” said William O’Neill, M.D.
DAIC
MARCH 31, 2025
mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J. mg can prevent heart attack and stroke in high-risk patients with established cardiovascular disease. Budoff, M.D.,
DAIC
DECEMBER 20, 2023
associate professor of biomedical research and translational medicine and scientific operations director at MMRI , recently published an innovative manuscript titled, Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Post-Myocardial Infarction. McCarthy, Ph.D. McCarthy, Ph.D., Rajendran JC Bose, Ph.D.,
Expert insights. Personalized for you.
105 
Let's personalize your content